Doctors should resample patient tissue should cancer spread, rather than relying on the initial biopsy, according to research focused on estrogen-positive breast cancer.
Using personal trackers (Fitbit et al), cancer researchers are trying to objectively measure patient quality life.
According to the Guardian, researchers captured data for 60 days from 41 people undergoing chemotherapy.
It’s not every day that researchers discover a new organ – one that might be implicated in how cancer spreads.
Continue reading “Scientists discover “new organ” which may be implicated in spread of cancer”
Breast, colon, lung and hematological cancers “have high rates” of acquired resistance to chemotherapy drugs, including aromatase inhibitors for breast cancer. This phenomena, multiple drug resistance (MDR), is a major impediment to long-term cancer treatment.
That makes this research, published online December 6, 2017, groundbreaking.
[We] present the important in vitro discovery that the development of MDR (in breast cancer cells) can be prevented, and that established MDR could be resensitized to therapy, by adjunct treatment with metformin (emphasis added).
Thirty percent of surveyed women with breast cancer reported skipping additional treatment following surgery.
The implication: these women were irrational.
Although the research paper was released in November, these women were diagnosed with cancer a decade ago, 2005-2007, and the data were collected almost a decade ago, 2007-2009.
Perhaps the most egregious part of this research is that it treats “breast cancer” as a singular disease rather than the extremely heterogenous entity that it is. And how relevant are the findings to today’s patient given the age of the data?